GPP tx Bio mas Colchicina!
Combination Therapy With Biologic and Colchicine for Generalized Pustular Psoriasis
TAKE-HOME MESSAGE
The authors report the case of 2 patients, a 48-year-old woman (patient 1) and a 28-year-old woman (patient 2), who were diagnosed with pustular psoriasis. Patient 1 was started on secukinumab, and patient 2 was started on guselkumab, both showing initial improvement at 3 to 4 weeks then worsening or recurrence at week 6 to week 8. At the time of worsening, both women were started on colchicine 1.5 mg daily in addition to continuing current biologic therapy. By week 20 (patient 1) and week 16 (patient 2), there was almost complete remission for both, respectively.
- The addition of low-dose colchicine may be useful in patients with pustular psoriasis refractory to biologic therapy alone. There have been gastrointestinal symptoms associated with this medication, but severe adverse effects at dermatologic doses have rarely been reported.
– Caroline K. Crabtree, MD
Abstract
Generalized pustular psoriasis (GPP) is a severe and multisystemic disease that is characterized by recurrent episodes of widespread and sterile pustules; however, there is no standard treatment for GPP.1, 2 Recently, targeted biological therapies, including TNF‐α, IL‐17, and IL‐23 inhibitors, have been shown to be highly effective for GPP.1, 2 However, in some patients, GPP cannot be adequately controlled via biologic monotherapy.3 In such cases, a combination therapy of biologics and other types of agents may be required.
Combination Therapy With Biologic and Colchicine for Generalized Pustular Psoriasis
Int. J. Dermatol 2020 Jun 03;[EPub Ahead of Print], R Taguchi, S Takamura, Y TerakiSent from my iPhone
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica
Skin Care Physicians of Costa Rica
Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574
Please excuse the shortness of this message, as it has been sent from
a mobile device.
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home